Strikingly, our data show a significantly upregulated expression of MID1 under disease-conditions, supporting our hypothesis that MID1 by pushing towards polyglutamine protein synthesis is a disease-modifier in HD and targeting of MID1 may represent one therapeutic approach to halt HD disease progression. This evidence concerns the gene MID1 and Huntington disease.